coagulation disorders
Start with the big picture
The topic begins with Virchow triad—blood-flow stasis, endothelial injury, and hypercoagulability—and the role of D-dimer in patients with low pre-test probability of VTE. It then surveys acute VTE treatment and contrasts LMWH, UFH, warfarin, and DOACs, including bridging, monitoring, bleeding management, and reversal agents. Special sections address antiphospholipid syndrome and heparin-induced thrombocytopenia. The lesson also covers aspirin and dual antiplatelet therapy after PCI, thrombolytic use and contraindications, and agents that support hemostasis, such as tranexamic acid and desmopressin. Together, these areas provide a framework for distinguishing clot-prevention strategies from treatments for bleeding disorders.
What you'll learn
- Describe how the components of Virchow triad contribute to thrombus formation.
- Explain the role of D-dimer in suspected VTE when pre-test probability is low.
- Distinguish key features of LMWH, UFH, warfarin, and DOAC therapy.
- Identify major topics in anticoagulant reversal, antiplatelet therapy, and thrombolysis.
- Summarize the roles of tranexamic acid and desmopressin in bleeding management.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
